Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5974
    -0.0032 (-0.53%)
     
  • NZD/EUR

    0.5533
    -0.0010 (-0.18%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    83.11
    +1.76 (+2.16%)
     
  • GOLD

    2,254.80
    +42.10 (+1.90%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.3590
    -0.4210 (-0.46%)
     

PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects

PerkinElmer, Inc. PKI recently announced CE-IVD mark for commercialization and distribution of its Vanadis NIPT (non-invasive prenatal testing) system throughout Europe and countries that recognize the marking. However, Vanadis NIPT is not available for clinical use in the United States yet.

The latest development is likely to fortify PerkinElmer’s hold in the global non-invasive prenatal testing market.

Following the announcement, shares of PerkinElmer rose 0.3% to $82.76 at close. Over the past year, shares of PerkinElmer have rallied 12.6% against the industry’s 5.7% decline. The current level is also higher than the S&P 500 index’s 1% rise.

The stock carries a Zacks Rank #3 (Hold).

More on Vanadis NIPT

Vanadis NIPT enables pregnant women to receive reliable and accurate cell free DNA-based screenings through a cost-efficient method. The non-invasive system provides screening results for trisomy 21, trisomy 18 and trisomy 13.

ADVERTISEMENT

The company has also collaborated with Women & Infants Hospital of Rhode Island to evaluate an innovative test method using Vanadis NIPT.

For investors’ notice, Sweden-based Vanadis Diagnostics was acquired by PerkinElmer in 2016, with a view to improve maternal and fetal health offerings.

A Peek Into NIPT Market

MarketsandMarkets opines that the global NIPT market is expected to reach $2.88 billion by 2021 at a CAGR of 16.4%. Growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT and launch of advanced NIPT products are fueling growth.

Hence the regulatory approval has been a well-timed one for the Massachusetts-based provider of scientific instruments.

Some key players in the space who deserve mention are Illumina ILMN and Natera NTRA. Notably, Illumina’s VeriSeq NIPT Solution and Natera’s Panorama next-generation NIPT are currently much in demand.

A Key Pick

A better-ranked stock in the broader medical space is Veeva Systems VEEV.

Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
 
PerkinElmer, Inc. (PKI) : Free Stock Analysis Report
 
Illumina, Inc. (ILMN) : Free Stock Analysis Report
 
Natera, Inc. (NTRA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research